Bristol Myers’ Opdivo keeps cancer at bay in more lymphoma patients than Seagen’s Adcetris in PhIII: #ASCO23news2023-06-04T15:38:30+00:00June 4th, 2023|Endpoints News|
Servier’s IDH1/2 inhibitor vorasidenib stalls brain cancer progression by 61% in PhIII study: #ASCO23news2023-06-04T12:00:07+00:00June 4th, 2023|Endpoints News|
AstraZeneca trial shows modest benefit in ovarian cancer, but doctors say it’s hard to apply findings: #ASCO23news2023-06-03T19:06:59+00:00June 3rd, 2023|Endpoints News|
Gilead, Arcus’ updated TIGIT data unlikely to resolve debates around space: #ASCO23news2023-06-03T17:30:12+00:00June 3rd, 2023|Endpoints News|
Perioperative Keytruda improves event-free survival in early NSCLC: #ASCO23news2023-06-03T14:19:26+00:00June 3rd, 2023|Endpoints News|
Roger Perlmutter lines up deals, fresh funding at Eikon; Second RSV vaccine approved; Several biotechs flashing red; and morenews2023-06-03T10:00:53+00:00June 3rd, 2023|Endpoints News|
Grail presents results of blood test study in patients suspected of cancer: #ASCO23news2023-06-02T19:11:50+00:00June 2nd, 2023|Endpoints News|
AtomVie raises $66M+ for new Ontario manufacturing sitenews2023-06-02T18:53:17+00:00June 2nd, 2023|Endpoints News|
NICE recommends Bristol Myers’ heart drug Camzyos in UKnews2023-06-02T18:38:10+00:00June 2nd, 2023|Endpoints News|
GSK campaign promotes routine vaccinations for adults in ‘critical moment for public health’news2023-06-02T18:22:55+00:00June 2nd, 2023|Endpoints News|
